Pratteln, Switzerland, April 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the latest progress on the commercial rollout of AGAMREE® for the treatment of Duchenne Muscular Dystrophy (DMD).

Dario Eklund, CEO of Santhera said: "The last 12 months have been a pivotal period for both the Company and DMD patients, as we began the global commercial roll-out of AGAMREE. Today, we are ...

Kye Pharmaceuticals announced it has submitted a New Drug Submission, or NDS, to Health Canada for the regulatory review and approval of ...

(CNW Group/Kye Pharmaceuticals Inc.) "Muscular Dystrophy Canada (MDC) is pleased that Health Canada has granted Priority Review for AGAMREE ® (vamorolone). While corticosteroids have been a key ...

Santhera's Duchenne muscular dystrophy (DMD) therapy Agamree has been cleared for NHS use after a confidential pricing agreement. The deal means that Agamree (vamorolone) will be available to ...

Santhera Pharmaceuticals (SIX: SANN) announces the latest progress on the commercial rollout of AGAMREE® for the treatment of Duchenne Muscular Dystrophy (DMD). Funding ...

Dario Eklund, CEO of Santhera said: "The last 12 months have been a pivotal period for both the Company and DMD patients, as we began the global commercial roll-out of AGAMREE. Today, we are ...

is pleased that Health Canada has granted Priority Review for AGAMREE ® (vamorolone). While corticosteroids have been a key treatment for decades, they are not currently approved for DMD ...

Pratteln, Switzerland, March 24, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that at its Capital Markets Day (CMD) in Zurich today, the Company will discuss the commercial progress with the ...